HK1116050A1 - Vegf antagonist formulations vegf - Google Patents

Vegf antagonist formulations vegf

Info

Publication number
HK1116050A1
HK1116050A1 HK08105425.6A HK08105425A HK1116050A1 HK 1116050 A1 HK1116050 A1 HK 1116050A1 HK 08105425 A HK08105425 A HK 08105425A HK 1116050 A1 HK1116050 A1 HK 1116050A1
Authority
HK
Hong Kong
Prior art keywords
vegf
antagonist formulations
formulations
fusion protein
lyophilized formulation
Prior art date
Application number
HK08105425.6A
Other languages
English (en)
Inventor
Daniel Dix
Kelly Frye
Susan Kautz
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36678320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1116050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1116050A1 publication Critical patent/HK1116050A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK08105425.6A 2005-03-25 2008-05-16 Vegf antagonist formulations vegf HK1116050A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66512505P 2005-03-25 2005-03-25
PCT/US2006/010600 WO2006104852A2 (en) 2005-03-25 2006-03-22 Vegf antagonist formulations

Publications (1)

Publication Number Publication Date
HK1116050A1 true HK1116050A1 (en) 2008-12-19

Family

ID=36678320

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105425.6A HK1116050A1 (en) 2005-03-25 2008-05-16 Vegf antagonist formulations vegf

Country Status (20)

Country Link
US (16) US20060217311A1 (xx)
EP (3) EP1861116B1 (xx)
JP (2) JP5376573B2 (xx)
KR (1) KR101327270B1 (xx)
CN (2) CN102614134B (xx)
AU (1) AU2006229930C1 (xx)
CA (3) CA3142945A1 (xx)
CY (2) CY1116980T1 (xx)
DK (2) DK1861116T3 (xx)
ES (2) ES2633574T3 (xx)
HK (1) HK1116050A1 (xx)
HU (2) HUE034109T2 (xx)
IL (2) IL185606A (xx)
LT (1) LT2586459T (xx)
NZ (1) NZ560713A (xx)
PL (2) PL1861116T3 (xx)
PT (2) PT1861116E (xx)
SI (2) SI1861116T1 (xx)
WO (1) WO2006104852A2 (xx)
ZA (1) ZA200708845B (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572893B2 (en) * 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
NZ560713A (en) 2005-03-25 2010-11-26 Regeneron Pharma VEGF antagonist formulations
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
CN103172750B (zh) 2007-11-01 2014-12-10 安斯泰来制药有限公司 免疫抑制性多肽与核酸
ES2836948T3 (es) * 2008-11-03 2021-06-28 Molecular Partners Ag Proteínas de unión que inhiben la interacción del receptor de VEGF-A
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
CN102552875B (zh) * 2010-12-09 2015-05-20 上海国健生物技术研究院 一种双功能vegf受体融合蛋白制剂
WO2012097019A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
US10864158B2 (en) * 2011-04-14 2020-12-15 The Regents Of The University Of California Multilayer thin film drug delivery device and methods of making and using the same
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN103957898B (zh) 2011-11-18 2016-02-24 瑞泽恩制药公司 聚合物蛋白微粒
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
WO2013138712A1 (en) * 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
CN104853763A (zh) * 2012-08-02 2015-08-19 赛诺菲 包含阿柏西普或ziv-阿柏西普的制品
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CN103110105A (zh) * 2012-11-14 2013-05-22 江苏江山制药有限公司 食品添加剂无糖维生素c钠盐颗粒的生产方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
LT3170005T (lt) 2014-07-18 2019-07-10 Sanofi Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
CN107206080B (zh) 2015-01-28 2022-07-08 辉瑞公司 稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
ES2956007T3 (es) 2015-12-03 2023-12-11 Regeneron Pharma Métodos de asociación de variantes genéticas con un resultado clínico en pacientes que padecen degeneración macular asociada a la edad tratados con anti-VEGF
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
AU2017341067B2 (en) 2016-10-07 2023-10-26 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
CA3043487A1 (en) * 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
USD849856S1 (en) 2017-06-28 2019-05-28 Jumpsport, Inc. Standing platform
ES2950570T3 (es) * 2017-07-25 2023-10-11 Jiangsu Hengrui Medicine Co Composición farmacéutica del complejo de proteína il-15 y usos de la misma
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
JP2021508687A (ja) * 2017-12-22 2021-03-11 サムスン バイオエピス カンパニー リミテッド Ｖｅｇｆアンタゴニストを含む液体組成物
JP2021511061A (ja) 2018-01-26 2021-05-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ｖｅｇｆ剤を使用した血管新生障害の治療のための方法および組成物
EP3761953A1 (en) 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
JOP20200275A1 (ar) * 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
CA3172625A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
KR102337471B1 (ko) * 2019-12-23 2021-12-09 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ES2435462T3 (es) * 1995-07-27 2013-12-19 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JPH09154588A (ja) * 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JPH10273450A (ja) 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
EP1655368B1 (en) 1999-04-16 2009-01-07 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
ES2223705T3 (es) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
CN1292655C (zh) 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
US7052691B2 (en) 2003-03-28 2006-05-30 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking VEGF-mediated activity
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
US20040266688A1 (en) 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
CA2519835A1 (en) 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
ITMI20031261A1 (it) 2003-06-20 2004-12-21 Messersi Packaging Srl Macchina reggiatrice con gruppo perfezionato di movimentazione della reggia.
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
JP2007501239A (ja) 2003-08-06 2007-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 放射線治療と組み合わせたｖｅｇｆアンタゴニストの使用
KR101471732B1 (ko) 2003-08-27 2014-12-16 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
EP1732947B1 (en) 2004-03-05 2011-04-27 Vegenics Pty Ltd Growth factor binding constructs materials and methods
EP1740168A2 (en) 2004-04-21 2007-01-10 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
CA2569108C (en) 2004-06-08 2012-08-21 Chengdu Kanghong Biotechnologies Co. Ltd Angiogenesis-inhibiting chimeric protein and the use
WO2005123104A2 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
JP2008503481A (ja) 2004-06-18 2008-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 悪性胸膜滲出液の処置のためのｖｅｇｆインヒビターの投与および使用の方法
CA2567795C (en) 2004-07-30 2013-06-11 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
NZ590132A (en) 2004-10-21 2012-03-30 Genentech Inc Dosage regime for treating intraocular neovascular diseases with VEGF
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
NZ560713A (en) 2005-03-25 2010-11-26 Regeneron Pharma VEGF antagonist formulations
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
MX368442B (es) 2014-01-25 2019-10-02 Chengdu Kanghong Biotechnologies Co Ltd Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma.
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
PT2586459T (pt) 2017-07-25
US20190388539A1 (en) 2019-12-26
US20120178683A1 (en) 2012-07-12
ES2548238T3 (es) 2015-10-15
AU2006229930B2 (en) 2010-08-05
KR101327270B1 (ko) 2013-11-08
US20160175439A1 (en) 2016-06-23
US8710004B2 (en) 2014-04-29
US20150079087A1 (en) 2015-03-19
NZ560713A (en) 2010-11-26
US11806398B2 (en) 2023-11-07
US20210393530A1 (en) 2021-12-23
JP2008535819A (ja) 2008-09-04
US8921316B2 (en) 2014-12-30
US20170073407A1 (en) 2017-03-16
KR20080015780A (ko) 2008-02-20
US10857231B2 (en) 2020-12-08
SI1861116T1 (sl) 2015-12-31
US9636400B2 (en) 2017-05-02
CA2598711A1 (en) 2006-10-05
US8110546B2 (en) 2012-02-07
PT1861116E (pt) 2015-11-04
US20170360930A1 (en) 2017-12-21
JP2013079270A (ja) 2013-05-02
LT2586459T (lt) 2017-09-25
US20210393778A1 (en) 2021-12-23
CA2598711C (en) 2018-05-29
ES2633574T3 (es) 2017-09-22
EP2586459B1 (en) 2017-05-24
IL227215A (en) 2016-02-29
ZA200708845B (en) 2010-07-28
IL185606A (en) 2013-08-29
US20210077624A1 (en) 2021-03-18
DK1861116T3 (en) 2015-11-09
CN101141975B (zh) 2012-05-23
DK2586459T3 (en) 2017-09-11
PL1861116T3 (pl) 2016-02-29
WO2006104852A3 (en) 2007-02-01
US20130261056A1 (en) 2013-10-03
US9511140B2 (en) 2016-12-06
US20210252147A1 (en) 2021-08-19
CN102614134A (zh) 2012-08-01
US20060217311A1 (en) 2006-09-28
US20100279933A1 (en) 2010-11-04
CN102614134B (zh) 2016-09-07
EP1861116B1 (en) 2015-09-16
HUE027096T2 (en) 2016-08-29
US10406226B2 (en) 2019-09-10
AU2006229930C1 (en) 2013-07-25
HUE034109T2 (en) 2018-01-29
EP2586459A1 (en) 2013-05-01
US20120101035A1 (en) 2012-04-26
CY1119243T1 (el) 2018-02-14
US8404638B2 (en) 2013-03-26
CA3142945A1 (en) 2006-10-05
JP5376573B2 (ja) 2013-12-25
EP1861116A2 (en) 2007-12-05
CY1116980T1 (el) 2017-04-05
US9416167B2 (en) 2016-08-16
US20210252105A1 (en) 2021-08-19
PL2586459T3 (pl) 2017-12-29
AU2006229930A1 (en) 2006-10-05
WO2006104852A2 (en) 2006-10-05
JP5752671B2 (ja) 2015-07-22
SI2586459T1 (sl) 2017-10-30
CA2995971A1 (en) 2006-10-05
EP3195874A1 (en) 2017-07-26
US20160244504A1 (en) 2016-08-25
CN101141975A (zh) 2008-03-12
IL185606A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
HK1116050A1 (en) Vegf antagonist formulations vegf
WO2007149334A3 (en) Vegf antagonist formulations suitable for intravitreal administration
MX2007002189A (es) Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
WO2006023665A3 (en) Il-1 antagonist formulations
AU2005211385A1 (en) Modified human growth hormone polypeptides and their uses
AR070690A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf (factor de crecimiento de fibroblastos)
SG160437A1 (en) Modified human growth hormone
HK1144684A1 (en) Igf-1 fusion polypeptides and therapeutic uses thereof igf-1
SG161209A1 (en) Formulations of human growth hormone comprising a non-naturally encoded amino acid
UA72915C2 (uk) Поживна ентеральна композиція, призначена для підтримки зростання та дозрівання недорозвинених шлунково-кишкових трактів у молодих ссавців та її застосування
WO2010027405A3 (en) Formulations of gc-c receptor agonist polypeptides
WO2004062555A3 (en) Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
PT2095822E (pt) Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry
WO2006106435A3 (en) Fusion protein comprising a hiv nef double mutant and its use therapy
ATE362765T1 (de) Milchsäurebakterien mit anxiolytischer wirkung, und ihre verwendungen
WO2006085954A3 (en) In vitro reconstitution of ribonucleoprotein complexes, and methods of use therefor
EP1307582A4 (en) NUCLEIC ACID CONSTRUCTS, TRANSFORMED VASCULAR CELLS, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR INDUCING ANGIOGENESIS
WO2004058803A3 (en) Peptides that bind of the vegfr-2
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
WO2006138026A8 (en) Stable pharmaceutical compositions including motilin-like peptides
WO2005105832A3 (en) Biologically active peptide vapeehptllteaplnpk derivatives
WO2007102946A3 (en) Crystalline polypeptides
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
WO2003048206A3 (fr) Peptides agonistes de l'hormone de croissance et leurs applications